ESPR FY 2023 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$116M+54.1% YoY

Gross Profit

$73M62.8% margin

Operating Income

-$156M-133.7% margin

Net Income

-$209M-179.9% margin

EPS (Diluted)

$-2.03

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$135M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$206M

Total Liabilities

$661M

Stockholders' Equity

-$455M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$116M	$75M	+54.1%
Gross Profit	$73M	$49M	+50.6%
Operating Income	-$156M	-$180M	+13.3%
Net Income	-$209M	-$234M	+10.4%